IN RE GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION, 20-md-2724 (E.D.Pa.)

The Radice Law Firm Represents direct purchasers in a class action lawsuit filed against dozens of generic drug manufacturers accused of fixing the prices of some 18 different generic drugs. The defendant drug manufacturers raised the prices for each of these drugs at alarming and unprecedented levels, frequently by more than 1,000 percent, and maintained those high prices for years. The case is currently pending before Judge Rufe in the Eastern District of Pennsylvania, who recently issued an Order and Opinion denying the defendants’ joint motion to dismiss the plaintiffs’ overarching conspiracy claims.

IN RE INCLUSIVE ACCESS COURSE MATERIALS ANTITRUST LITIGATION, 20-MD-2946 (S.D.N.Y.)

The Radice Law Firm was recently selected co-lead counsel for student purchaser plaintiffs in an antitrust action alleging a scheme by the dominant publishers (Pearson, McGraw Hill, and Cengage) and retailers (Barnes & Noble and Follett) of college textbooks to restrict sales of college textbooks to an online subscription format known as “Inclusive Access” in order to destroy the secondary market for textbooks, foreclose competition, and raise prices. The case is currently pending before Judge Cote in the Southern District of New York. 

In re Lantus Direct Purchaser Antitrust Litigation, No. 1:16-cv-12652 (D.Mass.)

Radice Law Firm is one of class counsel for direct purchaser plaintiffs in an antitrust action alleging a scheme by Sanofi to foreclose competition in the market for insulin glargine through improper Orange Book listings of device patents. The case is in discovery in the District of Massachusetts following the First Circuit’s remand in February 2020.

In re Intuniv Antitrust Litigation, No. 1:16-cv-12653 (D.Mass.)

Radice Law Firm is one of class counsel for direct purchaser plaintiffs in an antitrust action alleging an unlawful scheme by Shire and Actavis to monopolize the market for the ADHD medication Intuniv (guanfacine hydrochloride). The case is pending trial in the U.S. District Court for the District of Massachusetts following the court’s denial of Shire’s motions for summary judgment in October 2020.

In re Dental Supplies Antitrust Litigation, No. 1:16-cv-00696-BMC-GRB (E.D.N.Y.)

Radice Law Firm is court-appointed Liaison Counsel for plaintiffs in an antitrust class action alleging that four of the largest distributors of dental supplies and equipment colluded to artificially inflate the prices of dental supplies and equipment.

Read more ›

In re Capacitors Antitrust Litigation, No. 3:14-cv-03264-JD (N.D. Cal.)

Radice Law Firm is one of class counsel for plaintiffs in an antitrust class action alleging that manufacturers of capacitors (ubiquitous components found in virtually every electronic device) conspired to inflate capacitor prices.

Read more ›

Cung Le, et al. v. Zuffa, LLC, No. 2:15-cv-01045-RFB-PAL (D. Nev.)

Radice Law Firm is one of class counsel for mixed martial arts (MMA) fighter plaintiffs in an antitrust action alleging that Zuffa, LLC, which does business as the Ultimate Fighting Championship (UFC), is illegally controlling fighter services and sponsorship opportunities.

Read more ›

In re: Domestic Airline Travel Antitrust Litigation, No. 1:15-mc-01404-CKK (D.D.C.)

Radice Law Firm is one of class counsel for plaintiffs in an antitrust class action alleging several major airlines unlawfully conspired to inflate airfares by artificially constraining the supply in the market for domestic air travel.

Read more ›

In re Foreign Exchange Benchmark Rates Antitrust Litigation, No. 1:13-cv-07789-LGS (S.D.N.Y.)

Radice Law Firm is one of class counsel for plaintiffs in an antitrust action alleging that certain large banks engaged an unlawful scheme to manipulate the foreign exchange currency market.

Read more ›

In re Loestrin 24 Fe Antitrust Litigation, No. 1:13-md-02472-S-PAS (D.R.I.)

Radice Law Firm is one of class counsel for direct purchaser plaintiffs in an antitrust action alleging an unlawful scheme to monopolize the market for Loestrin 24 oral contraceptives.

Read more ›